Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles

Salman, Hesham; Gamazo, Carlos; Agüeros, Maite; Irache, Juan M.

doi:10.1016/j.vaccine.2007.09.044

Cited by 56 publications

(33 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pioneering work in this field investigated other insoluble particles, such as 500 nm rutile titanium dioxide, and demonstrated uptake by gut-associated lymphoid tissue (Jani et al, 1994). Other NM categories such as vitamin B1-coated NPs have also been tested in vivo (Salman et al, 2007). Similarly, Yuan et al (2007) characterized fluorescently labeled engineered lipid-based particles following intragastric administration to rats by gavage.…”

Section: In Vivo Animal Modelsmentioning

confidence: 99%

Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices

Venema²,

et al. 2014

View full text Add to dashboard Cite

Engineered metal/mineral, lipid and biochemical macromolecule nanomaterials (NMs) have potential applications in food. Methodologies for the assessment of NM digestion and bioavailability in the gastrointestinal tract are nascent and require refinement. A working group was tasked by the International Life Sciences Institute NanoRelease Food Additive project to review existing models of the gastrointestinal tract in health and disease, and the utility of these models for the assessment of the uptake of NMs intended for food. Gastrointestinal digestion and absorption could be addressed in a tiered approach using in silico computational models, in vitro non-cellular fluid systems and in vitro cell culture models, after which the necessity of ex vivo organ culture and in vivo animal studies can be considered. Examples of NM quantification in gastrointestinal tract fluids and tissues are emerging; however, few standardized analytical techniques are available. Coupling of these techniques to gastrointestinal models, along with further standardization, will further strengthen methodologies for risk assessment.

show abstract

Section: In Vivo Animal Modelsmentioning

confidence: 99%

Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices

Venema²,

et al. 2014

View full text Add to dashboard Cite

show abstract

“…1,7,[9][10][11][12] Many strategies exploit the binding of natural ligands to their receptors on GI cells (lectins, mannose, vitamin B 12 , thiamine, etc) or antibodies that recognize GI surface markers, which in some cases also induce uptake into cells. [13][14][15][16][17] Targeting approaches can in theory be combined with the use of protective compounds for oral formulations, such as chitosan, [18][19][20] controlled-release hydrogels, 8,21,22 and pH-sensitive polymers. [23][24][25] Strategies to facilitate mucus penetration can be additionally used, such as incorporation of chitosan, 18,19 polyethylene glycol, 12,26 surfactants, 27,28 or mucolytic agents.…”

Section: Introductionmentioning

confidence: 99%

Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice

Mane¹,

Muro²

2012

IJN

View full text Add to dashboard Cite

Drug delivery to the gastrointestinal (GI) tract is key for improving treatment of GI maladies, developing oral vaccines, and facilitating drug transport into circulation. However, delivery of formulations to the GI tract is hindered by pH changes, degradative enzymes, mucus, and peristalsis, leading to poor GI retention. Targeting may prolong residence of therapeutics in the GI tract and enhance their interaction with this tissue, improving such aspects. We evaluated nanocarrier (NC) and ligand-mediated targeting in the GI tract following gastric gavage in mice. We compared GI biodistribution, degradation, and endocytosis between control antibodies and antibodies targeting the cell surface determinant intercellular adhesion molecule 1 (ICAM-1), expressed on GI epithelium and other cell types. These antibodies were administered either as free entities or coated onto polymer NCs. Fluorescence and radioisotope tracing showed proximal accumulation, with preferential retention in the stomach, jejunum, and ileum; and minimal presence in the duodenum, cecum, and colon by 1 hour after administration. Upstream (gastric) retention was enhanced in NC formulations, with decreased downstream (jejunal) accumulation. Of the total dose delivered to the GI tract, ∼60% was susceptible to enzymatic (but not pHmediated) degradation, verified both in vitro and in vivo. Attenuation of peristalsis by sedation increased upstream retention (stomach, duodenum, and jejunum). Conversely, alkaline NaHCO 3 , which enhances GI transit by decreasing mucosal viscosity, favored downstream (ileal) passage. This suggests passive transit through the GI tract, governed by mucoadhesion and peristalsis. In contrast, both free anti-ICAM and anti-ICAM NCs demonstrated significantly enhanced upstream (stomach and duodenum) retention when compared to control IgG counterparts, suggesting GI targeting. This was validated by transmission electron microscopy and energy dispersive X-ray spectroscopy, which revealed anti-ICAM NCs in vesicular compartments within duodenal epithelial cells. These results will guide future work aimed at improving intraoral delivery of targeted therapeutics for the treatment of GI pathologies.

show abstract

“…1,2 The size-dependent immunoresponse against nanomaterials in various immune tissues (nanoimmunoresponse) is a new and attractive field, and mucosal immunity induction and enhancement using nanomaterials is a nanoimmunoresponse that is important to understand for developing new applications for nanomaterials.…”

Section: Introductionmentioning

confidence: 99%

“…4,[18][19][20] It has been previously reported that a mucosal nanoimmunoresponse occurred after using functionalized NPs of a single particle size. 2,[19][20][21] Also, intestinal IgA and serum HBsAg-specific total antibodies are specific mucosal nanoimmunoresponses against antigens and have been induced after oral administration of poly lactic-coglycolic acid (PLGA) microparticles (2-9 µm) plasmid DNA, which encoded HBsAg, 19 and PLGA NPs (390 nm), which encapsulated the hepatitis B surface antigen. 18 Additionally, the IgA, size-dependent nanoimmunoresponse in serum after oral administration of functionalized particles of various sizes has been reported.…”

Section: Introductionmentioning

confidence: 99%

Histochemical and biochemical analysis of the size-dependent nanoimmunoresponse in mouse Peyer's patches using fluorescent organosilica particles

Awaad¹,

Nakamura²,

Ishimura³

2012

IJN

View full text Add to dashboard Cite

Background/objective The size-dependent mucosal immunoresponse against nanomaterials (nanoimmunoresponse) is an important approach for mucosal vaccination. In the present work, the size-dependent nanoimmunoresponse of mouse Peyer’s patches (PPs) and immunoglobulin A (IgA) level was investigated using fluorescent thiol-organosilica particles. Methods Various sizes of fluorescent thiol-organosilica particles (100, 180, 365, 745, and 925 nm in diameter) were administered orally. PPs were analyzed histochemically, and IgA levels in PP homogenates, intestinal secretions around PPs, and bile were analyzed biochemically. Results When compared with the larger particles (745 and 925 nm), oral administration of smaller thiol-organosilica particles (100, 180, and 365 nm) increased the number of CD11b + macrophages and IgA + cells in the subepithelial domes of the PPs. Additionally, administration of larger particles induced the expression of alpha-L-fucose and mucosal IgA on the surface of M cells in the follicle-associated epithelia of PPs and increased the number of 33D1 + dendritic cells in the subepithelial domes of the PPs. IgA contents in the bile and PP homogenates were high after the administration of the 100 nm particles, but IgA levels in the intestinal secretions were high after the administration of the 925 nm particles. Two size-dependent routes of IgA secretions into the intestinal lumen, the enterohepatic route for smaller particles and the mucosal route for larger particles were proposed. Conclusion Thiol-organosilica particles demonstrated size-dependent nanoimmunoresponse after oral administration. The size of the particles may control the mucosal immunity in PPs and were useful in mucosal vaccination approaches.

show abstract

Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles

Cited by 56 publications

References 25 publications

Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices

Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices

Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice

Histochemical and biochemical analysis of the size-dependent nanoimmunoresponse in mouse Peyer's patches using fluorescent organosilica particles

Contact Info

Product

Resources

About